How many courses of treatment are needed for venetoclax/venetoclax combined with azacitidine to treat leukemia?

Venetoclax is a targeted drug that inhibits BCL-2 and is widely used to treat various types of leukemia, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It induces the apoptosis of leukemia cells by inhibiting the function ofBCL-2 protein. Azacitidine is a chemotherapy drug commonly used to treat leukemia, especially acute myeloid leukemia and myelodysplastic syndrome (MDS). The combination of venetoclax and azacitidine has shown significant results in patients with leukemia, especially those who cannot receive traditional chemotherapy.

The duration of combination therapy is usually determined based on the patient's condition and response to treatment. According to existing clinical studies, the treatment of acute myeloid leukemia with venetoclax combined with azacitidine usually requires 4 to 6 courses of treatment. The length of each treatment course is generally 28 days, where azacitidine is usually used on days 1 to 7 of each course, and venetoclax is taken orally once daily starting on day 1. Depending on the course of treatment, patients will need regular blood tests and imaging evaluations to evaluate the drug's efficacy and possible side effects.

In practical applications, the combination treatment of venetoclax and azacitidine can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients. Approximately 30% to 40% of patients with acute myeloid leukemia can achieve complete remission (CR) after 4 to 6 courses of treatment. If the patient responds well to treatment, treatment can be continued until the desired effect is achieved or unacceptable side effects occur.

However, the treatment of venetoclax combined with azacitidine is also accompanied by some adverse reactions, especially infections, anemia, thrombocytopenia and other problems, so monitoring and supportive care during treatment are particularly important. Doctors will adjust the treatment plan according to the patient's tolerance to ensure efficacy and safety.

Reference materials:https://www.venclexta.com/